Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF
Nonvitamin K-dependent oral anticoagulant agents (NOACs) are currently recommended for patients with atrial fibrillation at risk for stroke. As a group, NOACs significantly reduce stroke, intracranial hemorrhage, and mortality, with lower to similar major bleeding rates compared with warfarin. All NOACs are dependent on the kidney for elimination, such that patients with creatinine clearance
Source: Journal of the American College of Cardiology - Category: Cardiology Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Coumadin | Dialysis | Heart | Hemorrhagic Stroke | Stroke | Urology & Nephrology | Warfarin